Clinical trial · Observational
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
NCT00167999CI-TRIAL-00000641completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Escherichia Coli Infections | — | UNRESOLVED | — |
| Gram-Positive Bacterial Infections | — | UNRESOLVED | — |
| Klebsiella Infections | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| piperacillin-tazobactam | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Eligible patients of either sex, 15 years of age or older * Patients who are admitted to the department of hematology and oncology * Provide written informed consent Exclusion Criteria: * Patients who have hypersensitivity to β-lactam antibiotics * Female who are pregnant or breast-feeding * Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
References
Publications (0)
Data not yet available
No reference posted for this study.